Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
ABVC
vs
S&P 500
ABVC
S&P 500
Over the past 12 months, ABVC has underperformed S&P 500, delivering a return of -66% compared to S&P 500's +13% growth.
Stocks Performance
ABVC vs S&P 500
Performance Gap
ABVC vs S&P 500
Performance By Year
ABVC vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
ABVC Biopharma Inc
Glance View
ABVC Biopharma is a drug-development company that focuses on plant-based medicines. It works on turning natural compounds into prescription drug candidates, with a big emphasis on therapies for brain and nervous system conditions, cancer-related uses, and eye diseases. The company is not a mass-market drug seller; it is mainly a development-stage biotech that builds candidates, tests them, and tries to advance them through the regulatory process. The company makes money less by selling finished drugs and more by licensing its drug programs, signing research and development agreements, and earning fees tied to those partnerships. Its main customers and partners are usually other drug companies, research organizations, and clinical or commercial partners that want access to its compound library, drug candidates, or development know-how. In some cases, the value it offers is the rights to a molecule or program that another company can develop further. What makes ABVC’s business model different is that it sits upstream in the pharmaceutical value chain. Instead of running a large branded drug business, it tries to create intellectual property around botanical drug candidates and then partner them out. That means the company’s success depends on scientific progress, patent protection, and deal-making with larger industry players rather than on selling medicines directly to patients.
